Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Appropriations To Be Reconsidered By Conferees Following House Rejection

This article was originally published in The Pink Sheet Daily

Executive Summary

House voted 224 to 209 against the conference report which had included a provision to ban Medicare Part D coverage of erectile dysfunction drugs beginning Jan. 1, 2006.

You may also be interested in...



HHS Approps Conference Report Removes Ban On Erectile Dysfunction Drug Coverage

The new report, which comes up for a House vote as early as Dec. 14, includes offsets from CMS administrative costs and a public health emergency fund to continue ED drug coverage in 2006.

HHS Approps Conference Report Removes Ban On Erectile Dysfunction Drug Coverage

The new report, which comes up for a House vote as early as Dec. 14, includes offsets from CMS administrative costs and a public health emergency fund to continue ED drug coverage in 2006.

Medicare Erectile Dysfunction Drug Ban Becomes Law; Budget Process Avoids Part D

Legislation bars Medicare and Medicaid reimbursement for erectile dysfunction drugs, diverting the savings to fund low-income assistance programs and targeted measures to aid hurricane victims.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel